[go: up one dir, main page]

EP1608395A4 - Antikrebsmittel mit lk8-protein als wirkstoff - Google Patents

Antikrebsmittel mit lk8-protein als wirkstoff

Info

Publication number
EP1608395A4
EP1608395A4 EP04713257A EP04713257A EP1608395A4 EP 1608395 A4 EP1608395 A4 EP 1608395A4 EP 04713257 A EP04713257 A EP 04713257A EP 04713257 A EP04713257 A EP 04713257A EP 1608395 A4 EP1608395 A4 EP 1608395A4
Authority
EP
European Patent Office
Prior art keywords
protein
active ingredient
anticancer agent
anticancer
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04713257A
Other languages
English (en)
French (fr)
Other versions
EP1608395A1 (de
Inventor
Hyunkyung Yu
Jang-Seong Kim
Jin-Hyung Ahn
Ho-Jeong Lee
Kwan-Yub Kang
Hyung-Kwon Lim
In-Hwan Lim
Sung Geun Kim
Hak Kyu Joo
Jihyun Lee
Yeup Yoon
Doo-Hong Park
Jung Hwan Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Biotechnology Research Institute
Original Assignee
Mogam Biotechnology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Biotechnology Research Institute filed Critical Mogam Biotechnology Research Institute
Publication of EP1608395A1 publication Critical patent/EP1608395A1/de
Publication of EP1608395A4 publication Critical patent/EP1608395A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP04713257A 2003-02-20 2004-02-20 Antikrebsmittel mit lk8-protein als wirkstoff Withdrawn EP1608395A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR2003010797 2003-02-20
KR1020030010797A KR100595364B1 (ko) 2003-02-20 2003-02-20 Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
PCT/KR2004/000357 WO2004073730A1 (en) 2003-02-20 2004-02-20 Anticancer agent comprising lk8 protein as an active ingredient

Publications (2)

Publication Number Publication Date
EP1608395A1 EP1608395A1 (de) 2005-12-28
EP1608395A4 true EP1608395A4 (de) 2007-10-31

Family

ID=36116045

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04713257A Withdrawn EP1608395A4 (de) 2003-02-20 2004-02-20 Antikrebsmittel mit lk8-protein als wirkstoff

Country Status (9)

Country Link
EP (1) EP1608395A4 (de)
JP (1) JP2006518342A (de)
KR (1) KR100595364B1 (de)
CN (1) CN100546646C (de)
AU (1) AU2004212856B2 (de)
BR (1) BRPI0407611A (de)
CA (1) CA2516172A1 (de)
RU (1) RU2306147C2 (de)
WO (1) WO2004073730A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285277B2 (en) 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
KR20050090420A (ko) 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 메타스틴 유도체 및 이의 용도
US20070031379A1 (en) * 2004-01-09 2007-02-08 Lee Kyu H Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same
AU2005257484A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919062B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919064B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919063B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
EP2171467B1 (de) 2007-07-19 2016-01-13 bioMérieux Testverfahren für leber-fettsäurebindungsprotein, ace und ca19-9 zur in-vitro-diagnose von kolorektalkarzinom
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
WO2012067427A2 (ko) * 2010-11-16 2012-05-24 재단법인 목암생명공학연구소 Lk8 단백질을 유효성분으로 포함하는 당뇨망막병증 또는 노인성 황반변성의 예방 또는 치료용 약학 조성물
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743428B1 (en) * 1999-09-15 2004-06-01 Mogam Biotechnology Research Institute Angiogenesis inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KIM J-S ET AL: "Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 313, no. 3, 16 January 2004 (2004-01-16), pages 534 - 540, XP004481590, ISSN: 0006-291X *
KIM J-S ET AL: "Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a)", JOURNAL OF BIOLOGICAL CHEMISTRY 01 AUG 2003 UNITED STATES, vol. 278, no. 31, 1 August 2003 (2003-08-01), pages 29000 - 29008, XP002450345, ISSN: 0021-9258 *
See also references of WO2004073730A1 *
XUE S ET AL: "Apo(a) kringle V inhibits endothelial cell proliferation", FIBRINOLYSIS AND PROTEOLYSIS, vol. 14, no. Supplement 1, June 2000 (2000-06-01), & XVTH INTERNATIONAL CONGRESS ON FIBRINOLYSIS AND PROTEOLYSIS; HAMAMATSU, JAPAN; JUNE 25-29, 2000, pages 35, XP008083595, ISSN: 1369-0191 *
YU H-K ET AL: "Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles", CANCER RESEARCH 01 OCT 2004 UNITED STATES, vol. 64, no. 19, 1 October 2004 (2004-10-01), pages 7092 - 7098, XP002450346, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
AU2004212856B2 (en) 2007-07-19
RU2306147C2 (ru) 2007-09-20
KR100595364B1 (ko) 2006-07-03
JP2006518342A (ja) 2006-08-10
AU2004212856A1 (en) 2004-09-02
EP1608395A1 (de) 2005-12-28
WO2004073730A1 (en) 2004-09-02
KR20040075270A (ko) 2004-08-27
CA2516172A1 (en) 2004-09-02
RU2005129273A (ru) 2006-03-10
CN1753685A (zh) 2006-03-29
BRPI0407611A (pt) 2006-02-14
CN100546646C (zh) 2009-10-07

Similar Documents

Publication Publication Date Title
EP1608395A4 (de) Antikrebsmittel mit lk8-protein als wirkstoff
EP2093237A4 (de) Anti-hb-egf-antikörper als wirkstoff enthaltendes mittel für die krebstherapie
EP2078731A4 (de) Anti-hb-egf-antikörper als wirkstoff enthaltende pharmazeutische zusammensetzung
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
DE60328475D1 (de) Erwärmende, nicht irritierende gleitmittelzusammensetzung
EP1961764A4 (de) Zuckerkettenaddukt eines peptids und pharmazeutikum, das dieses als wirkstoff enthält
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
FR14C0069I2 (fr) Composition pharmaceutique comprenant le lurasidone
EP2196220A4 (de) Heilmittel gegen graft-versus-host-reaktion mit interleukin-6-rezeptorhemmer als wirkstoff
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
NO20053076D0 (no) Farmasoytisk formulering med en uloselig aktiv forbindelse.
DK1932522T3 (da) Terapeutisk middel mod leversygdom indeholdende 2-amino-1,3-propandiolderivat som aktiv bestanddel
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
EP2153831A4 (de) Antiermüdungsmittel und orale zusammensetzung, beide mit andrographolid als wirkstoff
UY27418A1 (es) Formulaciones en combinación de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilización
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
NO20064808L (no) Orale matrixformuleringer med licarbazepin
EP1900368A4 (de) Tablette mit einem kaum löslichen wirkstoff
ATE437679T1 (de) Wässrige antitranspirant formulierung
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
NO20073071L (no) Benzotiazolformuleringer og anvendelse av disse
EP2053038A4 (de) Aminoalkoholderivat und dieses als wirkstoff enthaltendes immunosuppressivum
NO20054214D0 (no) Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20070919BHEP

Ipc: A61P 35/04 20060101ALI20070919BHEP

Ipc: A61K 38/17 20060101AFI20070919BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20071002

17Q First examination report despatched

Effective date: 20100730

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130903